How many days does it take for Vyvanse (lisdexamfetamine) to be cleared from the body in a typical adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vyvanse Clearance Timeline

Vyvanse (lisdexamfetamine) is essentially cleared from your system within 2-3 days after the last dose, with the active metabolite d-amphetamine being 95% eliminated within 48 hours. 1, 2

Pharmacokinetic Profile

Prodrug (Lisdexamfetamine) Elimination

  • Lisdexamfetamine itself is rapidly eliminated with a half-life of less than 1 hour 1, 3
  • Plasma levels of the intact prodrug become undetectable by 6-8 hours after administration 1, 3
  • The prodrug is converted to d-amphetamine in red blood cells through enzymatic hydrolysis, not in the liver 1

Active Metabolite (d-Amphetamine) Elimination

  • d-Amphetamine has a half-life of 10-11.3 hours in adults 1, 4
  • 95% of d-amphetamine is eliminated within 48 hours after the final dose 2
  • Steady-state d-amphetamine levels are reached by day 5 of daily dosing 2
  • Peak plasma concentrations occur at approximately 4.4 hours after ingestion 1, 4

Complete System Clearance

For practical purposes, Vyvanse is cleared from the body in 2-3 days:

  • After 48 hours: 95% of the active d-amphetamine is eliminated 2
  • After 72 hours (3 days): Essentially complete elimination, given the 10-11 hour half-life means approximately 6-7 half-lives have passed 1, 4
  • By 5 days: No detectable accumulation occurs with repeated dosing, confirming complete clearance between this timeframe 2

Urinary Excretion Pattern

  • 96% of the administered dose is recovered in urine over 120 hours (5 days) 1, 3
  • 42% appears as amphetamine metabolites 1
  • 25% as hippuric acid 1
  • Only 2% as intact lisdexamfetamine 1
  • Less than 0.3% is excreted in feces 3

Clinical Caveats

Factors that may prolong clearance:

  • Renal impairment: Since 85-96% is renally excreted, kidney dysfunction will significantly delay elimination 1, 3
  • Urinary pH: Acidic urine increases amphetamine excretion, while alkaline urine prolongs it (though this is not explicitly stated in the Vyvanse literature, it applies to all amphetamines) 1
  • Age: Elderly patients may have slightly prolonged elimination due to reduced renal function 1

The 2-3 day clearance timeline assumes normal renal function and applies to both single doses and chronic daily use. 1, 2

Related Questions

Will citric acid affect the efficacy of Vyvanse (lisdexamfetamine) if taken one hour later?
Can a patient on 70 mg Vyvanse (lisdexamfetamine) safely add a 20 mg dextroamphetamine supplement?
Can a short-acting medication, such as Ritalin (methylphenidate) or Adderall (amphetamine and dextroamphetamine), be added as needed to a patient's regimen of Vyvanse (lisdexamfetamine) 40mg for days when only 5 hours of coverage is required due to a variable work schedule and difficulty sleeping when taking Vyvanse later than usual?
What is the equivalent dosage of dexamphetamine (Dextroamphetamine) when converting from Lisdexamphetamine (Vyvanse)?
Do adults who metabolize amphetamine quickly (e.g., on 25 mg Adderall XR) respond better to Vyvanse (lisdexamfetamine)?
What is the recommended albendazole dosing schedule and timing for treating Enterobius (pinworm) infection in children and adults?
What is the recommended albendazole dose for hookworm infection in a healthy individual older than two years, and what alternative regimens should be used for pregnant women, patients with severe malnutrition, chronic liver disease, or benzimidazole hypersensitivity?
Is there evidence that hydroxychloroquine (Plaquenil) 200 mg daily can modify subclinical autoimmunity and prevent progression to a defined connective‑tissue disease in an asymptomatic seropositive patient (e.g., positive ANA or anti‑Ro/La antibodies)?
How should a urinary tract infection caused by Pseudomonas aeruginosa in a female patient be interpreted and managed?
Can Entresto (sacubitril/valsartan) be used in a patient with end‑stage renal disease on hemodialysis who has heart failure with reduced ejection fraction, and how should it be initiated and monitored?
Is a drug holiday from Vyvanse (lisdexamfetamine) safe, and what are the recommended guidelines for implementing it in pediatric and adult patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.